Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Blastic plasmacytoid dendritic cell neoplasm. A study of three cases.

Sitges M, Vives S, Ribera JM.

Med Clin (Barc). 2019 Jul 23. pii: S0025-7753(19)30405-1. doi: 10.1016/j.medcli.2019.04.029. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
31350059
2.

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J, Zamora L, Morgades M, Vives S, Granada I, Montesinos P, Gómez-Seguí I, Mercadal S, Guàrdia R, Nomdedeu J, Pratcorona M, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, Ciudad J, Orfao A, González-Campos J, Barba P, Escoda L, Esteve J, Genescà E, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology.

Genes Chromosomes Cancer. 2019 Nov;58(11):815-819. doi: 10.1002/gcc.22788. Epub 2019 Aug 7.

PMID:
31340073
3.

Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.

Salamero O, Martínez-Cuadrón D, Sobas M, Benavente C, Vives S, De la Serna J, Pérez-Encinas M, Escoda L, Gil C, Brunet S, Ramos F, Esteve J, Amigo M, Krsnik I, Manso F, Arias J, González-Campos J, Serrano J, Oleksiuk J, Barrios M, García-Boyero R, Novo A, Sanz MA, Montesinos P; PETHEMA and PALG Groups.

Leuk Lymphoma. 2019 May 9:1-13. doi: 10.1080/10428194.2019.1607327. [Epub ahead of print]

PMID:
31068052
4.

Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease.

Hernández-Alvarez MI, Sebastián D, Vives S, Ivanova S, Bartoccioni P, Kakimoto P, Plana N, Veiga SR, Hernández V, Vasconcelos N, Peddinti G, Adrover A, Jové M, Pamplona R, Gordaliza-Alaguero I, Calvo E, Cabré N, Castro R, Kuzmanic A, Boutant M, Sala D, Hyotylainen T, Orešič M, Fort J, Errasti-Murugarren E, Rodrígues CMP, Orozco M, Joven J, Cantó C, Palacin M, Fernández-Veledo S, Vendrell J, Zorzano A.

Cell. 2019 May 2;177(4):881-895.e17. doi: 10.1016/j.cell.2019.04.010.

PMID:
31051106
5.

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.

Ribera JM, García O, Moreno MJ, Barba P, García-Cadenas I, Mercadal S, Montesinos P, Barrios M, González-Campos J, Martínez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genescà E, Bravo P, García-Belmonte D, García-Guiñón A, Hernández-Rivas JM, Feliu E; PETHEMA Group of the Spanish Society of Hematology.

Cancer. 2019 Aug 15;125(16):2810-2817. doi: 10.1002/cncr.32156. Epub 2019 Apr 23.

PMID:
31012967
6.

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.

Ribera J, Granada I, Morgades M, Vives S, Genescà E, González C, Nomdedeu J, Escoda L, Montesinos P, Mercadal S, Coll R, González-Campos J, Abella E, Barba P, Bermúdez A, Gil C, Tormo M, Pedreño M, Martínez-Carballeira D, Hernández-Rivas JM, Orfao A, Martínez-López J, Esteve J, Bravo P, Garcia-Guiñon A, Debén G, Moraleda JM, Queizán JA, Ortín X, Moreno MJ, Feliu E, Solé F, Ribera JM; PETHEMA Group, Spanish Society of Haematology.

Br J Haematol. 2019 Jul;186(2):263-268. doi: 10.1111/bjh.15887. Epub 2019 Mar 27.

PMID:
30916384
7.

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.

Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P.

Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019016. doi: 10.4084/MJHID.2019.016. eCollection 2019.

8.

A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.

Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group.

Leuk Res. 2019 Jan;76:1-10. doi: 10.1016/j.leukres.2018.11.006. Epub 2018 Nov 13.

9.

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.

Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genescà E, Martínez-Carballeira D, Martino R, Vives S, Guardia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez-Sanchez P, Amigo ML, Bermúdez A, Calbacho M, Hernández-Rivas JM, Feliu E, Orfao A, Ribera JM.

Eur J Haematol. 2019 Jan;102(1):79-86. doi: 10.1111/ejh.13178. Epub 2018 Nov 22.

PMID:
30267597
10.

Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis.

de la Guardia RD, Lopez-Millan B, Roca-Ho H, Bueno C, Gutiérrez-Agüera F, Fuster JL, Anguita E, Zanetti SR, Vives S, Nomdedeu J, Sackstein R, Lavoie J, Gónzalez-Rey E, Delgado M, Rosu-Myles M, Menendez P.

Haematologica. 2019 Feb;104(2):e54-e58. doi: 10.3324/haematol.2018.196568. Epub 2018 Sep 20. No abstract available.

11.

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.

Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM.

J Hematol Oncol. 2018 Jul 24;11(1):96. doi: 10.1186/s13045-018-0639-8.

12.

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, Barba P, Vives S, González-Campos J, Tormo M, Esteve J, López A, Moreno MJ, Ribera J, Alonso N, Bermúdez A, Amigo ML, Genescà E, García D, Vall-Llovera F, Bergua JM, Guàrdia R, Monteserín MC, Bernal T, Calbacho M, Martínez MP, Feliu E; PETHEMA Group.

Leuk Res. 2018 May;68:79-84. doi: 10.1016/j.leukres.2018.03.010. Epub 2018 Mar 19.

PMID:
29574396
13.

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups.

Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x.

PMID:
29473097
14.

A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups.

Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Erratum in: Ann Hematol. 2018 Feb 23;:.

PMID:
29392425
15.

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.

Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology.

Leuk Lymphoma. 2018 Jul;59(7):1634-1643. doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22.

PMID:
29165013
16.

Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation.

Torrent A, Ferrá C, Morgades M, Jiménez MJ, Sancho JM, Vives S, Batlle M, Moreno M, Xicoy B, Oriol A, Ibarra G, Ribera JM.

Med Clin (Barc). 2018 Jun 8;150(11):421-427. doi: 10.1016/j.medcli.2017.07.004. Epub 2017 Sep 2. English, Spanish.

PMID:
28874263
17.

Combining freeform optics and curved detectors for wide field imaging: a polynomial approach over squared aperture.

Muslimov E, Hugot E, Jahn W, Vives S, Ferrari M, Chambion B, Henry D, Gaschet C.

Opt Express. 2017 Jun 26;25(13):14598-14610. doi: 10.1364/OE.25.014598.

PMID:
28789044
18.

Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.

Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group and the Spanish Society of Hematology.

Genes Chromosomes Cancer. 2017 Nov;56(11):810-820. doi: 10.1002/gcc.22486. Epub 2017 Aug 26.

PMID:
28758283
19.

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes.

Diaz de la Guardia R, Lopez-Millan B, Lavoie JR, Bueno C, Castaño J, Gómez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco ML, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, Menéndez P.

Stem Cell Reports. 2017 Jun 6;8(6):1573-1586. doi: 10.1016/j.stemcr.2017.04.019. Epub 2017 May 18.

20.

Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma.

Sorigue M, Sancho JM, Pineda A, Garcia O, Lopez D, Moreno M, Tapia G, Batlle M, Ferra C, Vives S, Ibarra G, Feliu E, Ribera JM.

Leuk Res. 2017 Jul;58:98-101. doi: 10.1016/j.leukres.2017.05.001. Epub 2017 May 4.

PMID:
28521176
21.

Acute lymphoblastic leukemia in adults: Steps ahead.

Ribera JM, Vives S.

Med Clin (Barc). 2017 Aug 10;149(3):119-121. doi: 10.1016/j.medcli.2017.03.027. Epub 2017 Apr 26. English, Spanish. No abstract available.

PMID:
28456335
22.

Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose.

Sorigue M, Sancho JM, Morgades M, Moreno M, Grífols JR, Alonso E, Juncà J, Ferrà C, Batlle M, Vives S, Motlló C, García-Caro M, Navarro JT, Millà F, Feliu E, Ribera JM.

Leuk Lymphoma. 2017 Apr;58(4):916-922. doi: 10.1080/10428194.2016.1222378. Epub 2016 Aug 26.

PMID:
27561733
23.

Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.

Vives S, Oriol A, Piernas S, Brunet S, Clapés V, Guardia R, Subirà M, Sierra J, Ribera JM; CETLAM Group.

Eur J Haematol. 2015 Dec;95(6):576-82. doi: 10.1111/ejh.12538. Epub 2015 Mar 16.

PMID:
25692738
24.

Flow cytometry for detection of central nervous system disease in acute myeloid leukemia.

Sorigué M, Juncà J, Sancho JM, Morgades M, Esteban D, Navarro JT, Vives S, Feliu E, Ribera JM.

Leuk Lymphoma. 2015 Jul;56(7):2190-2. doi: 10.3109/10428194.2014.996752. Epub 2015 Mar 6. No abstract available.

PMID:
25641427
25.

Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.

Batlle M, Morgades M, Vives S, Ferrà C, Oriol A, Sancho JM, Xicoy B, Moreno M, Magallón L, Ribera JM.

Eur J Haematol. 2014 Dec;93(6):487-91. doi: 10.1111/ejh.12386. Epub 2014 Jun 21.

PMID:
24889275
26.

[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].

Fernández-Sojo J, Vives S, Oliveras Vilà T, Ribera JM.

Med Clin (Barc). 2014 Jul 7;143(1):43-4. doi: 10.1016/j.medcli.2013.09.009. Epub 2013 Oct 30. Spanish. No abstract available.

PMID:
24183124
27.

Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old.

Motlló C, Sancho JM, Grífols JR, Juncà J, Morgades M, Ester A, Rodríguez I, Vives S, Batlle M, Guardia R, Ferrà C, Gallardo D, Millá F, Feliu E, Ribera JM.

Cytotherapy. 2014 Mar;16(3):406-11. doi: 10.1016/j.jcyt.2013.08.005. Epub 2013 Oct 29.

PMID:
24176544
28.

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

Martínez-Cuadrón D, Montesinos P, Oriol A, Salamero O, Vidriales B, Bergua J, Herrera P, Vives S, Sanz J, Carpio C, Rodríguez-Veiga R, Moscardó F, Sanz MA.

Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.

PMID:
24081577
29.

Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma.

Vives S, Sancho JM, Almazán F, Juncà J, Grifols JR, Ribera JM.

J Clin Apher. 2012 Nov;27(5):260-2. doi: 10.1002/jca.21234. Epub 2012 May 7.

PMID:
22566276
30.

Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.

Sancho JM, Morgades M, Grifols JR, Juncà J, Guardia R, Vives S, Ferrà C, Batlle M, Ester A, Gallardo D, Millà F, Feliu E, Ribera JM.

Cytotherapy. 2012 Aug;14(7):823-9. doi: 10.3109/14653249.2012.681042. Epub 2012 Apr 27.

PMID:
22540329
31.

External occulter laboratory demonstrator for the forthcoming formation flying coronagraphs.

Landini F, Vives S, Venet M, Romoli M, Guillon C, Fineschi S.

Appl Opt. 2011 Dec 20;50(36):6632-44. doi: 10.1364/AO.50.006632.

PMID:
22193193
32.

Microarray time course experiments: finding profiles.

Irigoien I, Vives S, Arenas C.

IEEE/ACM Trans Comput Biol Bioinform. 2011 Mar-Apr;8(2):464-75. doi: 10.1109/TCBB.2009.79.

PMID:
21233526
33.

Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma.

Motlló C, Grau J, Juncà J, Ruiz N, Mate JL, Orna E, Navarro JT, Vives S, Sancho JM, Esteban D, Granada I, Feliu E, Ribera JM, Millá F.

Cancer Genet Cytogenet. 2010 Dec;203(2):328-32. doi: 10.1016/j.cancergencyto.2010.08.018.

PMID:
21156254
34.

Evaluation of enantioselective binding of fluoxetine to human serum albumin by ultrafiltration and CE--experimental design and quality considerations.

Asensi-Bernardi L, Martin-Biosca Y, Villanueva-Camañas RM, Medina-Hernández MJ, Vives SS.

Electrophoresis. 2010 Oct;31(19):3268-80.

PMID:
22216445
35.

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.

Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group.

Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9.

36.

Inferential clustering approach for microarray experiments with replicated measurements.

Salicrú M, Vives S, Zheng T.

IEEE/ACM Trans Comput Biol Bioinform. 2009 Oct-Dec;6(4):594-604. doi: 10.1109/TCBB.2008.106.

PMID:
19875858
37.

Active optics for high-dynamic variable curvature mirrors.

Hugot E, Ferrari M, Lemaitre GR, Madec F, Vives S, Chardin E, Le Mignant D, Cuby JG.

Opt Lett. 2009 Oct 1;34(19):3009-11. doi: 10.1364/OL.34.003009.

PMID:
19794798
38.

Treatment of olive-mill wastewater from a two-phase process by chemical oxidation on an industrial scale.

Nieto LM, Hodaifa G, Vives SR, Casares JA, Driss SB, Grueso R.

Water Sci Technol. 2009;59(10):2017-27. doi: 10.2166/wst.2009.165.

PMID:
19474497
39.

[Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient].

Vives S, Batlle M, Montané E, Ribera JM.

Med Clin (Barc). 2008 Nov 15;131(17):676. Spanish. No abstract available.

PMID:
19087798
40.

CLUM: a cluster program for analyzing microarray data.

Irigoien I, Fernandez E, Vives S, Arenas C.

Genetika. 2008 Aug;44(8):1137-40.

PMID:
18825964
41.

Statistical analysis of post mortem DNA damage-derived miscoding lesions in Neandertal mitochondrial DNA.

Vives S, Gilbert MT, Arenas C, Gigli E, Lao O, Lalueza-Fox C.

BMC Res Notes. 2008 Jul 10;1:40. doi: 10.1186/1756-0500-1-40.

42.

[High-dose ifosfamide and etoposide regimen as salvage and mobilization therapy for patients with lymphoma].

Vives S, Sancho JM, Juncà J, Grifols JR, Morgades M, Ribera JM.

Med Clin (Barc). 2008 Feb 16;130(5):172-4. Spanish.

PMID:
18341831
43.

[Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases].

Batlle M, Vall-Llovera F, Bechini J, Camps I, Marcos P, Vives S, Oriol A, Ribera JM.

Med Clin (Barc). 2007 Nov 10;129(17):660-3. Spanish.

PMID:
18005634
44.

[Hepatitis B virus reactivation after cessation of prophylaxis with lamivudine in a patient with non-Hodgkins lymphoma treated with chemotherapy and rituximab].

Vives S, Sancho JM, Planas R, Ribera JM.

Med Clin (Barc). 2006 Jun 3;127(1):39. Spanish. No abstract available.

PMID:
16796944
45.

[Interdigitating dendritic cell sarcoma with localization to the lung].

Vives S, Fernández MT, López de Castro PE, Ribera JM.

Med Clin (Barc). 2006 Apr 15;126(14):559. Spanish. No abstract available.

PMID:
16756917
46.

Accuracy in the estimation of quantitative minimal area from the diversity/area curve.

Vives S, Salicrú M.

Math Biosci. 2005 May;195(1):65-75.

PMID:
15893337
47.

SCHIP: statistics for chromosome interphase positioning based on interchange data.

Vives S, Loucas B, Vazquez M, Brenner DJ, Sachs RK, Hlatky L, Cornforth M, Arsuaga J.

Bioinformatics. 2005 Jul 15;21(14):3181-2. Epub 2005 May 10.

PMID:
15886279
48.

Cryogenic monolithic sapphire-rutile temperature compensated resonator oscillator.

Kersalé Y, Vives S, Meunier C, Giordano V.

IEEE Trans Ultrason Ferroelectr Freq Control. 2003 Dec;50(12):1662-6.

PMID:
14761036
50.

Survey and host fitness effects of red-cockaded woodpecker blood parasites and nest cavity arthropods.

Pung OJ, Carlile LD, Whitlock J, Vives SP, Durden LA, Spadgenske E.

J Parasitol. 2000 Jun;86(3):506-10.

PMID:
10864247

Supplemental Content

Support Center